- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05760092
The Use of Photobiomodulation in the Treatment of Oral Complaints of Long COVID-19.A Randomized Controlled Trial.
March 9, 2024 updated by: Rebeca Boltes Cecatto, University of Nove de Julho
The Use of Photobiomodulation in the Treatment of Oral Complaints of Long COVID-19. A Randomized Controlled Trial.
Coronavirus (COVID-19) is a newly emerging zoonotic agent that emerged in December 2019 in China (2019-nCoV) as a Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV -2).
Long COVID-19, or Post-Covid Syndrome or Long-term COVID-19, is a post-viral syndrome that persists after the acute infection has resolved.
The most frequent symptoms of Lonf-term COVID are fatigue and dyspnea.
But two classes of symptoms have been received scientific attention: the musculoskeletal pain and oral complaints related to Long COVID, mainly xerostomia and burning mouth.
Photobiomodulation (PBM) therapy is often used for oral diseases and presents itself as a non-invasive, low-cost, safe therapy that has benefits in relation to the quality of life of patients with xerostomia.
This study aims to investigate the clinical effectiveness of the use of a Photobiomodulation protocol in the treatment xerostomia and oral complaints related to Long-Covid.
This will be a single-center, randomized, controlled, blinded clinical trial that will involve patients with Long COVID in follow-up at the Medical and Multiprofessional outpatient clinic of University Nove de Julho (UNINOVE) which remained hospitalized with COVID-19 at Lydia Storópoli Universitarian Hospital during the year 2022 and who were discharged from the inpatient treatment from January to December 2022.
All those patients presenting xerostomia, burning mouth or oral complaints related to Long Covid will be randomized into 2 groups: PBM Group (standard rehabilitation treatment for Long COVID and xerostomia + PBM therapy) or PBM placebo group (standard rehabilitation treatment for Long COVID and xerostomia + placebo PBM therapy).
PBM consists of the application of Red LED on the 3 pairs of major salivary glands (parotid, submandibular and sublingual) extraorally, transcutaneously, 3 J/cm2, for 36 seconds, twice a week for 06 weeks.
Functional and quality of life evaluations will be perform pre and post therapy period.
Study Overview
Status
Completed
Conditions
Detailed Description
Coronavirus (COVID-19) is a newly emerging zoonotic agent that emerged in December 2019 in China (2019-nCoV) and which results in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV -2) The scientific literature has made progress in the characterization of the new coronavirus and works extensively on therapies and vaccines against the virus.
However, it is now known that SARS-CoV-2 is more than just an acute respiratory syndrome.
Long-term COVID-19, or Post-Covid Syndrome or Long-term COVID-19, is a post-viral syndrome that was first reported online in groups of COVID-19 survivors discussing their symptoms after the acute infection has resolved.
It begins to gain recognition in the scientific and medical communities.
Although a universally accepted definition does not yet exist, reviews have identified that the most frequent symptoms of Lonf-term COVID are fatigue and dyspnea.
But two classes of symptoms have been received scientific attention: the musculoskeletal pain and xerostomia.
Xerostomia is defined as a subjective sensation of dry mouth described by patients and which is commonly related to hyposalivation (decreased salivary flow rate).
The pathophysiology and clinical evolution of xerostomia in COVID-19 still lacks studies, but there are reports of 2 to 30% of patients presenting the complaint of dry mouth sensation even after the resolution of acute COVID.
Regular physical therapy, cognitive behavioral therapy have been used and encouraged in the follow-up of patients with post- COVID, demonstrating that even today these practices seem to be more promising than pharmacological treatment.
In parallel, studies demonstrate that Photobiomodulation (PBM) therapy is often used for oral diseases and presents itself as a non-invasive, low-cost, safe therapy that has benefits in relation to the quality of life of these patients.
PBM refers to a series of therapies in which non-ionizing light beams, including lasers, LEDs and broadband light in the visible and infrared spectra, are used to interact with biological tissues for different purposes.
In this sense, this study aims to investigate the clinical effectiveness of the use of a Photobiomodulation protocol in the treatment xerostomia related to Long-Covid.
This will be a single-center, randomized, controlled, blind clinical trial that will involve patients with Long-COVID in follow-up at the Medical and Multiprofessional outpatient clinic of University Nove de Julho (UNINOVE).
An analysis will be carried out of all medical records of patients who remained hospitalized with COVID-19 at Lydia Storópoli Universitary Hospital during the year 2022 and who were discharged from the inpatient treatment from January to December 2022, for a survey of telephone contact and epidemiological data collection by medical records.
All those patients who answer the questions referring to one or more symptoms related to the oral or nasal cavity, which have arisen after the onset of acute COVID infection, will be invited to participate in the study by making a first face-to-face evaluation at the University to confirm the diagnostic criteria of xerostomia, the diagnosis of Long COVID and evaluation of inclusion criteria in the study (adults with COVID-19 with complaints of xerostomia diagnosed more than 4 weeks after the acute infection and persisting for at least 02 months).
Pre- and post-treatment evaluations are composed by the Brazilian Version of the SF 36 Quality of Life Scale, salivary sialometry and salivary pH, Oral Health Impact Profile (OHIP-14), Abbreviated Xerostomia Inventory (SXI), Brazilian version of the Functional Independence Measure (FIM), Post -Covid-19 Functional Status Scale and WHO Disability Assessment Scale (WHODAS 2.0) All patients included will be randomized into 2 groups: PBM Group (standard rehabilitation treatment for Long COVID and xerostomia + PBM therapy) or PBM placebo group (standard rehabilitation treatment for Long COVID and xerostomia + placebo PBM therapy).
PBM consists of the application of Red LED on the 3 pairs of major salivary glands (parotid, submandibular and sublingual) extraorally, transcutaneously, 3 J/cm2, for 36 seconds, twice a week for 06 weeks.
The results will be sent for statistical analysis.
Study Type
Interventional
Enrollment (Actual)
10
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Rebeca B Cecatto, M.D., Ph.D.
- Phone Number: +5511970842496
- Email: rebeca.boltes@uni9.pro.br
Study Locations
-
-
-
Sao Paulo, Brazil
- Universidade Nove de Julho / Post-Graduate program Biophotonics Applied to Health Sciences
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Clinical diagnosis xerostomia related to Long-COVID;
- more than 4 weeks after the acute infection hat have persisted for at least 02 months (regardless of whether these patients are already using treatment for the complaints or not);
- Age greater than 18 years.
Exclusion Criteria:
- Clinical diagnosis of other previous rheumatological or musculoskeletal diseases that presents xerostomia;
- Previous use in the last 90 days of laser treatment or other photobiomodulation technique for the same or another indication;
- Clinical manifestations or complaints of xerostomia related to diseases other than Long COVID;
- Previous diseases of the oral or nasal cavity that occur with the symptom of xerostomia;
- Systemic inflammatory diseases (rheumatoid arthritis, Reiter's arthritis, ankylosing spondylitis, generalized polyarthritis, neoplasms);
- Uncontrolled metabolic or endocrine diseases;
- Neoplastic diseases;
- Serious cognitive or psychiatric disorders that that do not allow the understanding of the study;
- Steroid injections during the last 48 hours prior to baseline study assessment;
- Use of corticosteroids at an immunosuppressive dose (20mg daily of prednisone or equivalent for at least 14 days);
- Infection or tumor at the site of therapy application;
- Current chronic infections such as tuberculosis or chronic hepatitis treated or not;
- Severe blood dyscrasia;
- Blood clotting disorders (including thrombosis) at the application site;
- Psychoaffective disorder that prevents adherence to treatment;
- Signs, symptoms or laboratory changes suggestive of acute reinfection by COVID 19;
- Elevated resting heart rate (>100 beats/min);
- Low or high blood pressure (<90/60 or >140/90 mmHg);
- Low blood oxygen saturation (<95%) at rest, or dyspnea grade 3, 4, or 5 on the Medical Research Council Dyspnea Scale (KOVELIS et al., 2008), or exacerbation of dyspnea on exertion;
- Any condition where exercise is a contraindication such as decompensated heart disease, decompensated diabetes;
- Contraindications to the rehabilitation treatment of post-COVID syndrome recommended by the WHO: presence of heart disease after acute COVID, decrease in blood oxygen saturation after exercise (below 94% or decrease of at least 3% of the baseline saturation), presence of orthostatic hypotension;
- Any photosensitive disease or light sensitivity condition;
- Loss of follow-up at the follow-up clinical outpatient clinic, despite maintaining use of PBM according to the study protocol;
- Pregnancy;
- Any adverse effect on the previous use of PBM.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Photobiomodulation Therapy
Institutional standard treatment for xerostomia and COVID Longa + PBM therapy
|
(Medical follow-up at the general outpatient clinic for prescription and control of medications, underlying diseases, clinical status and routine short, medium and long-term care follow-up, standard guidelines for the use of aerobic physical activity in those who do not have contraindications, stretching exercises, ergonomics, home adaptation to maximize functionality and energy savings, emotional cognitive support psychotherapy, socio-educational measures, sleep hygiene, Nutritional follow-up and monitoring, dentistry follow-up at the University's odontological team, guidance on proper oral hygiene, use of low-sugar diets, daily topical use of fluoride and antimicrobial mouthwash to prevent dental caries, oral hydration, guidance on avoiding cigarette use or intake of caffeine-containing beverages .
When necessary, measures such as oral lubricants, artificial saliva, measures to prevent aspirations, as well as the careful use of liquids during meals, can be instituted ) +
Application of Red LED in the 3 pairs of major salivary glands (parotid, submandibular and sublingual) extraorally, transcutaneously, for 36 seconds, twice a week for 06 weeks.
Other Names:
|
Placebo Comparator: Placebo Photobiomodulation
Institutional standard treatment for xerostomia and COVID Longa + PBM placebo therapy
|
(Medical follow-up at the general outpatient clinic for prescription and control of medications, underlying diseases, clinical status and routine short, medium and long-term care follow-up, standard guidelines for the use of aerobic physical activity in those who do not have contraindications, stretching exercises, ergonomics, home adaptation to maximize functionality and energy savings, emotional cognitive support psychotherapy, socio-educational measures, sleep hygiene, Nutritional follow-up and monitoring, dentistry follow-up at the University's odontological team, guidance on proper oral hygiene, use of low-sugar diets, daily topical use of fluoride and antimicrobial mouthwash to prevent dental caries, oral hydration, guidance on avoiding cigarette use or intake of caffeine-containing beverages .
When necessary, measures such as oral lubricants, artificial saliva, measures to prevent aspirations, as well as the careful use of liquids during meals, can be instituted ) +
All parameters as the number of points, dose and place of application of the PBM will be the same as described in the item PBM therapy Intervention Group, however in the placebo PBM equipment will be turned off.
The device activation noise will be recorded and used to mimic the irradiation.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Brazilian version of the SF 36 Quality of Life Scale
Time Frame: pre-treatment and post-treatment moment (after 04 weeks of treatment)
|
Assessment of general quality of life, translated and validated for the Brazilian population, composed of assessments in the following domains: functional capacity, limitation due to physical aspects, pain, general health status, vitality, social aspects, emotional aspects and mental health.
|
pre-treatment and post-treatment moment (after 04 weeks of treatment)
|
Nutritional assessment
Time Frame: pre-treatment and post-treatment (after 04 weeks of treatment)
|
Anthropometric measurements of body weight, height and calculation of the Body Mass Index (BMI) according to the World Health Organization (WHO) reference standard for adults and Lipschitz criterion for elderly patients.
|
pre-treatment and post-treatment (after 04 weeks of treatment)
|
Salivary ph, Stimulated salivary flow and unstimulated salivary flow
Time Frame: pre-treatment and post-treatment (after 04 weeks of treatment)
|
Total salivary flow rates (SFRs) at rest and during stimulation will be determined according to the guidelines for unstimulated and stimulated total saliva collection provided by Navazesh and Kumar (1993).
To characterize hyposalivation, investigators will use the Sreebny criterion (2000) according to which the abnormal salivary flow is lower than 0.1 ml/min without stimulation and 0.5 ml/min with stimulation.
Salivary pH (unstimulated salivary flow) will also be evaluated, which will be performed using pH indicator paper tape, color scale ranging from 0.0 to 14.0 (gradation 1.0; precision 0.2) The strips will be dipped in samples of saliva for 5 min.
Then the test fields of the strips will be compared with the color scales.
Whereas healthy saliva must have a pH between 6.5 to 7.4.
|
pre-treatment and post-treatment (after 04 weeks of treatment)
|
Oral Health Impact Profile (OHIP-14)
Time Frame: pre-treatment and post-treatment (after 04 weeks of treatment)
|
Assessment of Oral Health-related Quality of Life, by OHIP-14 , translated and validated for Brazilian population
|
pre-treatment and post-treatment (after 04 weeks of treatment)
|
Xerostomia Inventory XI
Time Frame: pre-treatment and post-treatment (after 04 weeks of treatment)
|
A multi-item approach to measuring and quantify dry mouth.
|
pre-treatment and post-treatment (after 04 weeks of treatment)
|
Functional Independence Measure (FIM)
Time Frame: pre-treatment and post-treatment (after 04 weeks of treatment)
|
A translated and validated for the Brazilian population of general assessment of functional independence
|
pre-treatment and post-treatment (after 04 weeks of treatment)
|
Post-Covid-19 Functional Status Scale
Time Frame: pre-treatment and post-treatment (after 04 weeks of treatment)
|
A tool to measure the full spectrum of functional outcomes following COVID-19.
|
pre-treatment and post-treatment (after 04 weeks of treatment)
|
The World Health Organization Disability Assessment Schedule (WHODAS 2.0)
Time Frame: pre-treatment and post-treatment (after 04 weeks of treatment)
|
The World Health Organization Disability Assessment Schedule (WHODAS 2.0) was designed to assess the functioning level in six life domains (cognition, mobility, selfcare, getting along, life activities, and participation in community activities)
|
pre-treatment and post-treatment (after 04 weeks of treatment)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Rebeca B Cecatto, M.D., Ph.D., University of Nove de Julho
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Chowdhury F, Grigoriadou S, Bombardieri M. Severity of COVID-19 infection in primary Sjogren's syndrome and the emerging evidence of COVID-19-induced xerostomia. Clin Exp Rheumatol. 2021 Nov-Dec;39 Suppl 133(6):215-222. doi: 10.55563/clinexprheumatol/k7x3ta. Epub 2021 Dec 16.
- Verma H, Shah J, Akhilesh K, Shukla B. Patients' perspective about speech, swallowing and hearing status post-SARS-CoV-2 (COVID-19) recovery: E-survey. Eur Arch Otorhinolaryngol. 2022 May;279(5):2523-2532. doi: 10.1007/s00405-021-07217-2. Epub 2022 Jan 21.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 1, 2023
Primary Completion (Actual)
February 1, 2024
Study Completion (Actual)
March 8, 2024
Study Registration Dates
First Submitted
September 20, 2022
First Submitted That Met QC Criteria
March 7, 2023
First Posted (Actual)
March 8, 2023
Study Record Updates
Last Update Posted (Actual)
March 12, 2024
Last Update Submitted That Met QC Criteria
March 9, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Coronavirus Infections
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Virus Diseases
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Pneumonia, Viral
- Pneumonia
- Lung Diseases
- Disease Attributes
- Stomatognathic Diseases
- Mouth Diseases
- Salivary Gland Diseases
- Chronic Disease
- Post-Infectious Disorders
- COVID-19
- Xerostomia
- Post-Acute COVID-19 Syndrome
Other Study ID Numbers
- Covidlongasusy
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaRecruitingCOVID-19 Pneumonia | COVID-19 Respiratory Infection | COVID-19 Pandemic | COVID-19 Acute Respiratory Distress Syndrome | COVID-19-Associated Pneumonia | COVID 19 Associated Coagulopathy | COVID-19 (Coronavirus Disease 2019) | COVID-19-Associated ThromboembolismGreece
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
Clinical Trials on Institutional standard treatment for xerostomia and Long Covid
-
Koç UniversityTerminatedCovid19 | Sarcopenia | Intensive Care Unit Acquired WeaknessTurkey
-
Adhera Health, Inc.Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi...Completed
-
University of Colorado, DenverActive, not recruiting
-
Dermama Bioteknologi LaboratoriumKementerian Riset dan Teknologi / Badan Riset dan Inovasi Nasional, IndonesiaRecruitingSARS-CoV2 InfectionIndonesia
-
Scripps Translational Science InstituteCue HealthRecruitingImmunoCARE: Rapid, Accurate COVID Testing to Reduce Hospitalization of Immunocompromised IndividualsHIV Infections | Lymphoma | Leukemia | Cancer | Multiple Myeloma | Immunosuppression | Immunodeficiency | Transplant | Graft Versus Host Disease | Age-Related ImmunodeficiencyUnited States
-
Jessa HospitalHasselt UniversityCompletedRadiation Dermatitis | Radiodermatitis; AcuteBelgium
-
Cadila PharnmaceuticalsCouncil of Scientific and Industrial Research, IndiaCompleted
-
Ain Shams UniversityRecruiting
-
Indonesia UniversityCompletedCovid19 | AcupunctureIndonesia
-
AtriCure, Inc.Recruiting